1. Nuttall, G. Experimente über die bacterienfeindlichen Einflüsse des thierischen Körpers. Z. Hyg. Infektionskr. 4, 353–394 (1888).
2. Ehrlich, P. & Morgenroth, J. Ueber haemolysine—zweite mittheilung. Berl. Klin. Wochenschr., 481–486 (1899).
3. US Food and Drug Administration. FDA approves first-of-its-kind drug to treat rare blood disorder (USFDA, Rockville, MD, USA) ( http://www.fda.gov/bbs/topics/NEWS/2007/NEW01589.html ) (March 16, 2007).
4. Sunyer, J.O., Zarkadis, I.K. & Lambris, J.D. Complement diversity: a mechanism for generating immune diversity? Immunol. Today 19, 519–523 (1998).
5. Walport, M.J. Complement. First of two parts. N. Engl. J. Med. 344, 1058–1066 (2001).